Crescita Therapeutics Inc.
CTX.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 98.22% | 117.82% | 57.05% | -26.55% | -36.50% |
| Total Depreciation and Amortization | 7.76% | 2.50% | -7.20% | -14.83% | -10.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -363.38% | -341.85% | -95.43% | -59.57% | -74.18% |
| Change in Net Operating Assets | -95.49% | -58.45% | -42.34% | 387.27% | 112.05% |
| Cash from Operations | -59.96% | 84.56% | 60.67% | 451.92% | 28.42% |
| Capital Expenditure | 47.56% | 24.86% | -34.85% | -1,505.20% | -1,458.31% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 52.11% | 21.54% | -27.37% | -1,446.89% | -1,400.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.78% | -6.93% | -6.81% | -7.67% | -8.09% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 30.31% | 24.24% | 42.97% | 39.49% | 18.58% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 50.00% | 0.00% | 0.00% | 0.00% | -- |
| Cash from Financing | 10.07% | 9.95% | 20.31% | 17.21% | -8.40% |
| Foreign Exchange rate Adjustments | -118.69% | 378.57% | 65.93% | 369.09% | 396.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -408.92% | 92.97% | 33.55% | -30.48% | -111.22% |